Clinical Trial

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Name: To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. — clinical trial record (NCT07303465)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.

Trial Details

NCT Number	NCT07303465
Lead Sponsor	Ranok Therapeutics (Hangzhou) Co., Ltd.
Conditions	KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment	60 participants
Start Date	2025-10-14
Primary Completion	2026-11-30 (estimated)
Study Completion	2026-11-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-24